Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The budget impact of implementing atrial fibrillation-screening in European countries

  • Eklund, Michaela
  • Bernfort, Lars|||0000-0003-0537-3319
  • Appelberg, Kajsa
  • Engler, Daniel|||0000-0002-9519-6258
  • Schnabel, Renate B.|||0000-0001-7170-9509
  • Martinez, Carlos
  • Wallenhorst, Christopher
  • Boriani, Giuseppe|||0000-0002-9820-4815
  • Buckley, Claire M.
  • Diederichsen, Søren Zöga
  • Svendsen, Jesper Hastrup
  • Montaner, Joan|||0000-0003-4845-2279
  • Potpara, Tatjana|||0000-0001-6285-6902
  • Levin, Lars-Åke|||0000-0003-2581-4863
  • Lyth, Johan|||0000-0002-4988-6346
A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers' costs, introducing population screening for AF will result in savings of stroke-related costs.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study

  • Palà, Elena
  • Bustamante, Alejandro
  • Clúa-Espuny, Josep Lluis
  • Acosta, Juan
  • Gonzalez-Loyola, Felipe
  • Dos Santos, Sara
  • Ribas-Segui, Domingo
  • Ballesta-Ors, Juan
  • Penalba, Anna
  • Giralt, Marina
  • Lechuga-Duran, Iñigo
  • Gentille-Lorente, Delicia
  • Pedrote, Alonso
  • Muñoz, Miguel Ángel
  • Montaner, Joan
[Background and objective] AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring., [Methods] 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (NuuboTM), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck., [Results] AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p<0.001) was the only independent biomarker to detect AF in the whole cohort. Compared to an ECG, WatchBP had the highest sensitivity (84.6%) and AUC (0.895 [0.780–1]), while MyDiagnostick showed the highest specificity (97.10%)., [Conclusion] The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible., This work was supported by Fundació Marató de TV3 in the research call “La Marató 2014: malalties del cor” [grant number: 201528-30-31-3]. EP received a predoctoral grant from Vall d’Hebron Institute of Research. Neurovascular Research Laboratory also takes part in the Span-ish stroke research network INVICTUS+ [RD16/0019]. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation pro-gramme under grant agreement N°847770., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke

  • Palà, Elena
  • Pagola, Jorge
  • Juega, Jesus
  • Francisco-Pascual, Jaume
  • Penalba, Anna
  • Rodíiguez, Maite A.
  • Lera Alfonso, Mercedes de
  • Arenillas, Juan F.
  • Cabezas, Juan A.
  • Moniche, Francisco
  • Torres-Chacón, Reyes de
  • Pérez-Sánchez, Soledad
  • González-Alujas, Teresa
  • Molina, Carlos A.
  • Bustamante, Alejandro
  • Montaner, Joan
[Background] Atrial fibrillation (AF) is one of the most prevalent causes of cryptogenic stroke. Also, apart from AF itself, structural and remodelling changes in the atria might be an underlying cause of cryptogenic stroke. We aimed to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and peak atrial longitudinal strain (PALS), in patients with cryptogenic stroke., [Methods] An aptamer array (including 1310 proteins) was measured in the blood of 20 cryptogenic stroke patients monitored during 28 days with a Holter device as a case-control study of the Crypto-AF cohort. Protein levels were compared between patients with (n = 10) and without AF (n = 10) after stroke, and the best candidates were tested in 111 patients from the same cohort (44 patients with AF and 67 without AF). In addition, in the first 20 patients, proteins were explored according to PALS and LAVI values., [Results] Forty-six proteins were differentially expressed in AF cases. Of those, four proteins were tested in a larger sample size. Only DPP7, presenting lower levels in AF patients, was further validated. Fifty-seven proteins correlated with LAVI, and 270 correlated with PALS. NT-proBNP was common in all the discovery analyses performed. Interestingly, many proteins and pathways were altered in patients with low PALS., [Conclusions] Multiple proteins and pathways related to AF and atrial cardiomyopathy have been revealed. The role of DPP7 as a biomarker for stroke aetiology should be further explored. Moreover, the present study may be considered hypothesis-generating., This work was supported by the Instituto de Salud Carlos III, Spain [grant number PI15/02265 and PI18/00804]. The Spanish stroke research network INVICTUS+ (RD16/0019/00021) of the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund, FEDER) is also acknowledged. EP has received a predoctoral grant from Vall D’Hebron Institute of Research. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation program under grant agreement N°847770., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Common and specific proteins and pathways in heart and cerebral ischemia

  • Palà, Elena
  • García-Rodríguez, Paula
  • Bustamante, Alejandro
  • Penalba, Anna
  • Lamana-Vallverdú, Marcel
  • Guamán-Pilco, Daisy R.
  • Delgado, Pilar
  • Riba, Iolanda
  • Jiménez-Balado, Joan
  • Planas, Alejandra
  • Simó-Servat, Olga
  • Escudero-Martínez, Irene
  • Montaner, Joan
[Objective] To understand the similarities and differences between acute ischemic stroke and acute myocardial infarction (AMI) to help in the development of specific or common treatment strategies., [Methods] Using an aptamer-based proteomic array, we measured and compared 1310 circulating proteins in the blood of 40 patients with AIS, 9 patients with AMI, and 31 healthy controls. Pathway enrichment analysis was performed using GSEA and g:profiler., [Results] Ninety-four proteins were differentially expressed in AIS, and 284 were differentially expressed in AMI. Of these, 8 were specific to cerebral ischemia, and 197 were specific to myocardial infarction. Forty-two proteins were altered in both ischemia processes. Most altered pathways in AIS could be classified as immune response, cell cycle processing, molecular transport, or signaling. Pathways altered in AMI were mostly related to lipid metabolism and transport, highlighting cholesterol metabolic processes and estrogen signaling. In both types of ischemia, we found pathways related to metabolism, specifically purine metabolism, and signaling processes, such as TNF signaling or MAPK1/3., [Conclusions] The present study revealed proteins and pathways that were specifically altered in cerebral ischemia, in cardiac ischemia, or in both diseases, providing information on the similarities and differences of ischemic conditions. The role of common and specific proteins and pathways should be explored in detail to find possible therapeutic targets., This work was supported by the Instituto de Salud Carlos III (PI18/00804). The Neurovascular research laboratory is part of the Spanish stroke research RICORS (RD16/0019/00021). Also, part of the authors was funded by the European Union's Horizon 2020 research and innovation program (grant agreements 847770, 754517, and 733379). Also, the funding of the studies from which patients were used are detailed: PRECISED study was supported by an Integrative Excellence Project by the Spanish Institute of Health, Instituto de Salud Carlos III, grant PIE 2013/27, CIBER CV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares), CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas asociadas), and the European Regional Development Fund (ERDF- FEDER); PARIAS study was funded by the Spanish Ministry of Economy, Industry and Competitiveness (Grant RTC-2016-5300-1), the Junta de Andalucía (Grant PIN- 0144-2016), the European Project ITRIBIS, and the Fundación Cajasol; COMBAT-MI was sponsored with a Grant from Instituto de Salud Carlos III (PIE 13/00027), and a Grant from Generalitat de Catalunya (PERIS SLT/2381/2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The budget impact of implementing atrial fibrillation-screening in European countries

  • Eklund, Michaela
  • Bernfort, Lars
  • Appelberg, Kajsa
  • Engler, Daniel
  • Schnabel, Renate B.
  • Martínez Giménez, José Carlos
  • Wallenhorst, Christopher
  • Boriani, Giuseppe
  • Buckley, Claire M.
  • Diederichsen, Søren Zöga
  • Svendsen, Jesper Hastrup
  • Montaner, Joan
  • Potpara, Tatjana
  • Levin, Lars-Åke
  • Lyth, Johan
A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers' costs, introducing population screening for AF will result in savings of stroke-related costs., This work has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU). Data from the LOOP Study was used and LOOP was supported by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union’s Horizon 2020 program [grant number 847770 to the AFFECT-EU consortium], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic. R.B.S. has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation. From the European Union’s Horizon Europe research and innovation programme under the grant agreement No. 101095480 (HYPERMAKER)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study

  • Pala Vila, Elena
  • Bustamante Rangel, Alejandro
  • Clua-Espuny, Jose L.
  • Acosta, Juan
  • Gonzalez-Loyola, Felipe
  • Dos Santos, Sara
  • Penalba Morenilla, Anna
  • Montaner Villalonga, Joan
  • Giralt Arnaiz, Marina
Biomarkers; Electrocardiography; Blood plasma, Biomarcadores; Electrocardiografía; Plasma sanguíneo, Biomarcadors; Electrocardiografia; Plasma sanguini, Background and objective AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring. Methods 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (NuuboTM), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck. Results AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p<0.001) was the only independent biomarker to detect AF in the whole cohort. Compared to an ECG, WatchBP had the highest sensitivity (84.6%) and AUC (0.895 [0.780–1]), while MyDiagnostick showed the highest specificity (97.10%). Conclusion The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible., This work was supported by Fundació Marató de TV3 in the research call “La Marató 2014: malalties del cor” [grant number: 201528-30-31-3]. EP received a predoctoral grant from Vall d’Hebron Institute of Research. Neurovascular Research Laboratory also takes part in the Span-ish stroke research network INVICTUS+ [RD16/0019]. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation pro-gramme under grant agreement N°847770. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The budget impact of implementing atrial fibrillation-screening in European countries

  • Eklund, Michaela
  • Bernfort, Lars
  • Appelberg, Kajsa
  • Engler, Daniel
  • Schnabel, Renate B
  • Martinez, Carlos
  • Montaner Villalonga, Joan
Atrial fibrillation; Budget impact; Screening, Fibril·lació auricular; Impacte pressupostari; Cribatge, Fibrilación auricular; Impacto presupuestario; Cribado, A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers’ costs, introducing population screening for AF will result in savings of stroke-related costs., This work has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU). Data from the LOOP Study was used and LOOP was supported by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union’s Horizon 2020 program [grant number 847770 to the AFFECT-EU consortium], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic. R.B.S. has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation. From the European Union’s Horizon Europe research and innovation programme under the grant agreement No. 101095480 (HYPERMAKER).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

General practitioners’ perceptions on opportunistic single-time point screening for atrial fibrillation: A European quantitative survey

  • Vermunicht, Paulien
  • Grecu, Mihaela
  • Buckley, Claire M.
  • Pala Vila, Elena
  • Mairesse, Georges H.
  • Deharo, Jean-Claude
Atrial fibrillation; General practitioners; Survey, Fibrilación auricular; Médicos de cabecera; Encuesta, Fibril·lació auricular; Metges de capçalera; Enquesta, Background: There is no clear guidance on how to implement opportunistic atrial fibrillation (AF) screening in daily clinical practice. Objectives: This study evaluated the perception of general practitioners (GPs) about value and practicalities of implementing screening for AF, focusing on opportunistic single-time point screening with a single-lead electrocardiogram (ECG) device. Methods: A descriptive cross-sectional study was conducted with a survey developed to assess overall perception concerning AF screening, feasibility of opportunistic single-lead ECG screening and implementation requirements and barriers. Results: A total of 659 responses were collected (36.1% Eastern, 33.4% Western, 12.1% Southern, 10.0% Northern Europe, 8.3% United Kingdom & Ireland). The perceived need for standardized AF screening was rated as 82.7 on a scale from 0 to 100. The vast majority (88.0%) indicated no AF screening program is established in their region. Three out of four GPs (72.1%, lowest in Eastern and Southern Europe) were equipped with a 12-lead ECG, while a single-lead ECG was less common (10.8%, highest in United Kingdom & Ireland). Three in five GPs (59.3%) feel confident ruling out AF on a single-lead ECG strip. Assistance through more education (28.7%) and a tele-healthcare service offering advice on ambiguous tracings (25.2%) would be helpful. Preferred strategies to overcome barriers like insufficient (qualified) staff, included integrating AF screening with other healthcare programs (24.9%) and algorithms to identify patients most suitable for AF screening (24.3%). Conclusion: GPs perceive a strong need for a standardized AF screening approach. Additional resources may be required to have it widely adopted into clinical practice., The AFFECT-EU project has received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation program under the grant agreement no. 847770.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

General practitioners' perceptions on opportunistic single-time point screening for atrial fibrillation, A European quantitative survey

  • Vermunicht, Paulien
  • Grecu, Mihaela
  • Deharo, Jean-Claude|||0000-0002-1534-3845
  • Buckley, Claire M.
  • Palà, Elena|||0000-0002-1074-990X
  • Mairesse, Georges H.
  • Farkowski, Michal M|||0000-0003-1673-7712
  • Bergonti, Marco
  • Pürerfellner, Helmut
  • Hanson, Coral L.
  • Neubeck, Lis
  • Freedman, Ben|||0000-0002-3809-2911
  • Witt, Henning|||0000-0001-6256-3763
  • Hills, Mellanie T.
  • Lund, Jenny
  • Giskes, Katrina
  • Engler, Daniel|||0000-0002-9519-6258
  • Schnabel, Renate B.|||0000-0001-7170-9509
  • Heidbuchel, Hein
  • Desteghe, Lien
There is no clear guidance on how to implement opportunistic atrial fibrillation (AF) screening in daily clinical practice. This study evaluated the perception of general practitioners (GPs) about value and practicalities of implementing screening for AF, focusing on opportunistic single-time point screening with a single-lead electrocardiogram (ECG) device. A descriptive cross-sectional study was conducted with a survey developed to assess overall perception concerning AF screening, feasibility of opportunistic single-lead ECG screening and implementation requirements and barriers. A total of 659 responses were collected (36.1% Eastern, 33.4% Western, 12.1% Southern, 10.0% Northern Europe, 8.3% United Kingdom & Ireland). The perceived need for standardized AF screening was rated as 82.7 on a scale from 0 to 100. The vast majority (88.0%) indicated no AF screening program is established in their region. Three out of four GPs (72.1%, lowest in Eastern and Southern Europe) were equipped with a 12-lead ECG, while a single-lead ECG was less common (10.8%, highest in United Kingdom & Ireland). Three in five GPs (59.3%) feel confident ruling out AF on a single-lead ECG strip. Assistance through more education (28.7%) and a tele-healthcare service offering advice on ambiguous tracings (25.2%) would be helpful. Preferred strategies to overcome barriers like insufficient (qualified) staff, included integrating AF screening with other healthcare programs (24.9%) and algorithms to identify patients most suitable for AF screening (24.3%). GPs perceive a strong need for a standardized AF screening approach. Additional resources may be required to have it widely adopted into clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Influence of geographical latitude on vitamin D status, cross-sectional results from the BiomarCaRE consortium

  • Oskarsson, Viktor|||0000-0002-2936-2895
  • Salomaa, Veikko|||0000-0001-7563-5324
  • Eliasson, Mats|||0000-0002-2866-8972
  • Reinikainen, Jaakko|||0000-0002-7825-5359
  • Männistö, Satu|||0000-0002-8668-3046
  • Palmieri, Luigi|||0000-0002-4298-2642
  • Donfrancesco, Chiara|||0000-0002-8040-5571
  • Sans, Susana|||0000-0002-0400-5197
  • Costanzo, Simona|||0000-0003-4569-1186
  • de Gaetano, Giovanni|||0000-0002-7823-1402
  • Iacoviello, Licia|||0000-0003-0514-5885
  • Veronesi, Giovanni|||0000-0002-4119-6615
  • Ferrario, Marco M.|||0000-0003-2741-7124
  • Padró, Teresa|||0000-0003-1921-954X
  • Thorand, Barbara
  • Huth, Cornelia|||0000-0003-2421-433X
  • Zeller, Tanja|||0000-0003-3379-2641
  • Blankenberg, Stefan|||0000-0001-6488-2362
  • Anderson, Annie|||0000-0002-0047-4500
  • Tunstall-Pedoe, Hugh|||0000-0001-8721-7058
  • Kuulasmaa, Kari|||0000-0003-2165-1411
  • Söderberg, Stefan|||0000-0001-9225-1306
Even though sunlight is viewed as the most important determinant of 25-hydroxyvitamin D (25(OH)D) status, several European studies have observed higher 25(OH)D concentrations among north-Europeans than south-Europeans. We studied the association between geographical latitude (derived from ecological data) and 25(OH)D status in six European countries using harmonised immunoassay data from 81 084 participants in the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project (male sex 48·9 %; median age 50·8 years; examination period 1984-2014). Quantile regression models, adjusted for age, sex, decade and calendar week of sampling and time from sampling to analysis, were used for between-country comparisons. Up until the median percentile, the ordering of countries by 25(OH)D status (from highest to lowest) was as follows: Sweden (at 65·6-63·8°N), Germany (at 48·4°N), Finland (at 65·0-60·2°N), Italy (at 45·6-41·5°N), Scotland (at 58·2-55·1°N) and Spain (at 41·5°N). From the 75th percentile and upwards, Finland had higher values than Germany. As an example, using the Swedish cohort as a comparator, the median 25(OH)D concentration was 3·03, 3·28, 5·41, 6·54 and 9·28 ng/ml lower in the German, Finnish, Italian, Scottish and Spanish cohort, respectively (P-value < 0·001 for all comparisons). The ordering of countries was highly consistent in subgroup analyses by sex, age, and decade and season of sampling. In conclusion, we confirmed the previous observation of a north-to-south gradient of 25(OH)D status in Europe, with higher percentile values among north-Europeans than south-Europeans.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study

  • Pala Vila, Elena
  • Bustamante Rangel, Alejandro
  • Clua-Espuny, Jose L.
  • Acosta, Juan
  • Gonzalez-Loyola, Felipe
  • Dos Santos, Sara
  • Penalba Morenilla, Anna
  • Montaner Villalonga, Joan
  • Giralt Arnaiz, Marina
Biomarkers; Electrocardiography; Blood plasma, Biomarcadores; Electrocardiografía; Plasma sanguíneo, Biomarcadors; Electrocardiografia; Plasma sanguini, Background and objective AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring. Methods 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (NuuboTM), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck. Results AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p<0.001) was the only independent biomarker to detect AF in the whole cohort. Compared to an ECG, WatchBP had the highest sensitivity (84.6%) and AUC (0.895 [0.780–1]), while MyDiagnostick showed the highest specificity (97.10%). Conclusion The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible., This work was supported by Fundació Marató de TV3 in the research call “La Marató 2014: malalties del cor” [grant number: 201528-30-31-3]. EP received a predoctoral grant from Vall d’Hebron Institute of Research. Neurovascular Research Laboratory also takes part in the Span-ish stroke research network INVICTUS+ [RD16/0019]. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation pro-gramme under grant agreement N°847770. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The budget impact of implementing atrial fibrillation-screening in European countries

  • Eklund, Michaela
  • Bernfort, Lars
  • Appelberg, Kajsa
  • Engler, Daniel
  • Schnabel, Renate B
  • Martinez, Carlos
  • Montaner Villalonga, Joan
Atrial fibrillation; Budget impact; Screening, Fibril·lació auricular; Impacte pressupostari; Cribatge, Fibrilación auricular; Impacto presupuestario; Cribado, A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers’ costs, introducing population screening for AF will result in savings of stroke-related costs., This work has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU). Data from the LOOP Study was used and LOOP was supported by Innovation Fund Denmark [grant number 12-1352259], The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation [grant number 11-04-R83-A3363-22625], Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, the European Union’s Horizon 2020 program [grant number 847770 to the AFFECT-EU consortium], Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat, and an unrestricted grant from Medtronic. R.B.S. has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 847770 (AFFECT-EU) and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation. From the European Union’s Horizon Europe research and innovation programme under the grant agreement No. 101095480 (HYPERMAKER).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

General practitioners’ perceptions on opportunistic single-time point screening for atrial fibrillation: A European quantitative survey

  • Vermunicht, Paulien
  • Grecu, Mihaela
  • Buckley, Claire M.
  • Pala Vila, Elena
  • Mairesse, Georges H.
  • Deharo, Jean-Claude
Atrial fibrillation; General practitioners; Survey, Fibrilación auricular; Médicos de cabecera; Encuesta, Fibril·lació auricular; Metges de capçalera; Enquesta, Background: There is no clear guidance on how to implement opportunistic atrial fibrillation (AF) screening in daily clinical practice. Objectives: This study evaluated the perception of general practitioners (GPs) about value and practicalities of implementing screening for AF, focusing on opportunistic single-time point screening with a single-lead electrocardiogram (ECG) device. Methods: A descriptive cross-sectional study was conducted with a survey developed to assess overall perception concerning AF screening, feasibility of opportunistic single-lead ECG screening and implementation requirements and barriers. Results: A total of 659 responses were collected (36.1% Eastern, 33.4% Western, 12.1% Southern, 10.0% Northern Europe, 8.3% United Kingdom & Ireland). The perceived need for standardized AF screening was rated as 82.7 on a scale from 0 to 100. The vast majority (88.0%) indicated no AF screening program is established in their region. Three out of four GPs (72.1%, lowest in Eastern and Southern Europe) were equipped with a 12-lead ECG, while a single-lead ECG was less common (10.8%, highest in United Kingdom & Ireland). Three in five GPs (59.3%) feel confident ruling out AF on a single-lead ECG strip. Assistance through more education (28.7%) and a tele-healthcare service offering advice on ambiguous tracings (25.2%) would be helpful. Preferred strategies to overcome barriers like insufficient (qualified) staff, included integrating AF screening with other healthcare programs (24.9%) and algorithms to identify patients most suitable for AF screening (24.3%). Conclusion: GPs perceive a strong need for a standardized AF screening approach. Additional resources may be required to have it widely adopted into clinical practice., The AFFECT-EU project has received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation program under the grant agreement no. 847770.